Arena Pharmaceuticals, Inc. Picks Japan’s Eisai Inc. To Market Obesity Drug Lorcaserin In Deal Worth $1.3 Billion Potentially

AP -- Arena Pharmaceuticals Inc. said Thursday it has an agreement with Japan's Eisai Inc. in a deal worth potentially more than $1.3 billion to fund commercialization of an obesity drug that could become Arena's first product.